Diabetes Bexagliflozine Dulaglutide IND Exenatide IND Finerenon Kerendia is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults. Extension of indication to include the treatment of chronic kidney disease (CKD) and for the prevention of cardiovascular (CV) events in adults with CKD (regardless of the stage of albuminuria) associated with type 2 diabetes IND Insulin lispro IND Insuline Icodec Polyethylene glycol loxenatide Regulatoire T-cellen (TREGS) Sotagliflozine IND Teplizumab Tirzepatide Liver diseases Arachidyl amido cholanoic acid Maralixibat Seladelpar Metabolic diseases ALXN1840 Autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells transduced ex vivo using a lentiviral vector encoding the human arylsulfatase A gene Avalglucosidase alfa Bardoxolone Methyl Cipaglucosidase alfa / miglustat Empagliflozine IND Fexapotide Fezolinetant Fosdenopterin Leriglitazone Liraglutide IND Lixivaptan Lonafarnib Octreotide Olenasufligene relduparvovec Olipudase alfa Palovarotene Pariglasgene brecaparvovec Pegunigalsidase alfa RGX-121 Reloxaliase Somapacitan Somatrogon Sparsentan TransCon PTH (palopegteriparatide) Other metabolism and Endocrinology Abaloparatide Treatment of osteoporosis in postmenopausal women at increased risk of fracture Treatment of osteoporosis. Alpelisib Burosumab IND Corifollitropin alfa IND Ganirelix G Linzagolix IND Ospemifene IND Pegzilarginase Semaglutide For weight management in people with obesity or who are overweight and have other related conditions. Extension of indication to include treatment of adolescents for weight management for Wegovy. IND Setmelanotide Imcivree is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 6 years of age and above. IMCIVREE is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed Bardet‑Biedl syndrome (BBS), loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 6 years of age and above. IND Vosoritide Unknown Diazoxide choline (controlled-release tablet) Levonorgestrel G Linzagolix Lonapegsomatropin Lumasiran Mirabegron IND Relugolix IND Relugolix / estradiol / norethisteronen Sofpironium bromide Vibegron